Article
TP53 mutation and survival in aggressive B cell lymphoma.
International journal of cancer - 1 Oct 2017
Zenz Thorsten, Kreuz Markus, Fuge Maxi, Klapper Wolfram, Horn Heike, Staiger Annette M, Winter Doris, Helfrich Hanne, Huellein Jennifer, Hansmann Martin-Leo, Stein Harald, Feller Alfred, Möller Peter, Schmitz Norbert, Trümper Lorenz, Loeffler Markus, Siebert Reiner, Rosenwald Andreas, Ott German, Pfreundschuh Michael, Stilgenbauer Stephan
Abstract excerpt
TP53 is mutated in 20-25% of aggressive B-cell lymphoma (B-NHL). To date, no studies have addressed the impact of TP53 mutations in prospective clinical trial cohorts. To evaluate the impact of TP53 mutation to current risk models in aggressive B-NHL, we investigated TP53 gene mutations within the RICOVER-60 trial. Of 1,222 elderly patients (aged 61-80 years) enrolled in the study and randomized to six or eight...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.